14th October 2022 | Pharma Updates

Latest pharmaceutical industry news and updates

*Refresh the page if the below document does not appear.

India's reputation as pharmaceutical hub at stake

In light of the two unfortunate incidents that happened during the last month, which includes death of Gambian children due to substandard drugs and death of five people in Chandigarh, the public confidence in Indian drugs might get reduced and the industry as a whole might have to suffer losses.

Biological E plans to separate non-vaccine business from others and sell equity stakes

The Hyderabad-based private firm stated that they are actively considering the fact of separating their non-vaccine business and selling the equity stakes to investors to raise required funds. Furthermore, the Managing Director said that they want to make this decision sooner than later.

Roche's SMA drug shows promising results in the largest trial ever

On Wednesday, the leading pharmaceutical company announced that its product Evrysdi (risdiplam), indicated for the treatment of the genetic disorder, Spinal Muscular Atrophy (SMA), has shown encouraging outcomes. The results came from the fresh two-year-old data from the largest ever “Jewelfish” study.

Multiple reasons found to support Maiden Pharma's ban

After the issuance of the show-cause notice on October 7, the state drug control authority gave the company a week’s time to revert. The use of toxic solvent, contaminated solvents without conducting proper tests, and discrepancies in manufacturing dates are among the 12 faults that were found to support the ban decision.

Teva Pharma notifies Adderall shortage projection to last through March

US FDA announced the unavailability of the drug through a website posting. The drug makers informed the regulatory authority that the manufacturing and supply delays might last through March next year. The drug is used for the treatment of attention deficit hyperactivity disorder and narcolepsy.

GSK's highly effective vaccine to win the RSV vaccine race

The interpretation of the data revealed GSK’s respiratory syncytial virus (RSV) vaccine to be 82.6% effective in a cautiously watched latestage study involving old aged adults. The company’s chief scientific officer stated that these are very promising results as RSV is still one of the major infectious diseases without any vaccine available.

Relmada's depression drug fails to give positive outcomes in late-stage trial

The therapeutics company’s experimental treatment for major depressive disorder failed to give promising results in a highly anticipated late-stage trial. The drug failed to show statistically significant improvement in the symptoms of depression in patient subjects when compared to a placebo.

Update profile

Please update your profile to keep using the website

Start chat
Need Help?
PharmaState Academy
Hello, how can we help you?